JPWO2017172771A5 - - Google Patents

Info

Publication number

JPWO2017172771A5

JPWO2017172771A5 JP2018551440A JP2018551440A JPWO2017172771A5 JP WO2017172771 A5 JPWO2017172771 A5 JP WO2017172771A5 JP 2018551440 A JP2018551440 A JP 2018551440A JP 2018551440 A JP2018551440 A JP 2018551440A JP WO2017172771 A5 JPWO2017172771 A5 JP WO2017172771A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

weeks

administration

patient

per

Prior art date

2024-02-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims description 34
• 238000000034 method Methods 0.000 claims description 33
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 16
• 150000001413 amino acids Chemical group 0.000 claims description 10
• 201000004681 Psoriasis Diseases 0.000 claims description 8
• 229960002885 histidine Drugs 0.000 claims description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
• CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 claims description 6
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
• 229930006000 Sucrose Natural products 0.000 claims description 6
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 6
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 6
• 229920000053 polysorbate 80 Polymers 0.000 claims description 6
• 229940068968 polysorbate 80 Drugs 0.000 claims description 6
• 239000005720 sucrose Substances 0.000 claims description 6
• 239000003085 diluting agent Substances 0.000 claims description 5
• 229940079593 drug Drugs 0.000 claims description 5
• 239000003814 drug Substances 0.000 claims description 5
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
• 229960000485 methotrexate Drugs 0.000 claims description 4
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
• 239000002458 cell surface marker Substances 0.000 claims description 2
• 239000003246 corticosteroid Substances 0.000 claims description 2
• 230000005847 immunogenicity Effects 0.000 claims description 2
• 229960003444 immunosuppressant agent Drugs 0.000 claims description 2
• 239000003018 immunosuppressive agent Substances 0.000 claims description 2
• 229960004641 rituximab Drugs 0.000 claims description 2
• 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims description 2
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 2
• 238000005303 weighing Methods 0.000 claims 4
• 239000000203 mixture Substances 0.000 claims 2
• 229960001334 corticosteroids Drugs 0.000 claims 1
• 230000000139 costimulatory effect Effects 0.000 claims 1
• 201000010099 disease Diseases 0.000 description 6
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
• MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 4
• 229960003824 ustekinumab Drugs 0.000 description 4
• 238000011221 initial treatment Methods 0.000 description 3
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 208000025705 Axial Spondyloarthritis Diseases 0.000 description 1
• 206010009900 Colitis ulcerative Diseases 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 201000006704 Ulcerative Colitis Diseases 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 229960002874 briakinumab Drugs 0.000 description 1
• 229950010864 guselkumab Drugs 0.000 description 1
• 230000001861 immunosuppressant effect Effects 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 238000012423 maintenance Methods 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 229950007943 risankizumab Drugs 0.000 description 1
• 201000000306 sarcoidosis Diseases 0.000 description 1
• 229940071598 stelara Drugs 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 229950005515 tildrakizumab Drugs 0.000 description 1
• 238000011282 treatment Methods 0.000 description 1